COVID - 19
SARS-COV-2 is a strain of coronavirus that causes severe respiratory illness. The virus enters cells via the human ACE2 (ACE2) receptor via the viral spike protein (s-protein)1. This key interaction of viral entry through ACE2 allows the virus to hijack the cellular replication machinery, overload the patient’s immune system, and can cause death in severe cases.
Our company specializes in life sciences consulting with in-house capabilities in therapeutic protein design and drug development. We are currently developing a unique anti-COVID-19 (SARS-COV-2) biologics platform, from which lead compounds for a novel coronavirus blocking combinatorial therapy have been generated.
Our novel SARS-COV-2 blocking combinatorial therapy built by our proprietary in-silico modeling platform works in tandem to inhibit SARS-COV-2 viral entry and to block viral replication if the virus is already inside a patient’s cells. This front-line therapy is advantageous because it can be used immediately when a patient is infected with the virus. This is in stark contrast to vaccines which require the patient to have an uncompromised immune system and can take up to 6 weeks to be efficacious.
Moreover, this in-silico biological platform can easily be leveraged to make high affinity blockers to other genetic cousins of SARS-COV-2 such as MERS-COV. In fact, we already have in-silico MERS-COV inhibitors in our pipeline that are ready for validation as future therapeutics.
Our work has passed Phase I of both NIH ACTIV, NSF SBIR grant review, and we are currently actively evaluating partnerships with biotech, pharma and other research institutes. If interested in partnership discussions, please contact us.